Oral bioavailability and pharmacokinetics of DRF-4367, a new cox-2 inhibitor in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 2, 2003, Pages 137-141

  Ramesh, Mullangi ^a   Mamidi, Rao N V S ^a   Jagannath, Kota ^a   Singh, Sunil Kumar ^a   Rao, Kalleda Srinivasa ^a   Rao, Yeleswarapu Koteswar ^a   Seshagirirao, Casturi ^a   Rajagopalan, Ramanujam ^a   Srinivas, Nuggehally R ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Bioavailability; COX 2 inhibitor; DRF 4367; Pharmacokinetics; Rats

Indexed keywords

2 HYDROXYMETHYL 4 [5 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H 1 PYRAZOLYL] 1 BENZENESULFONAMIDE; CYCLOOXYGENASE 2 INHIBITOR; DRF 4367; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT;

EID: 0038780872     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190502     Document Type: Article

References (11)

1. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P. (1994): Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA; 91: 12013-12017.
2. David L DeWitt (1999): COX-2 selective inhibitors: The new super aspirins. Mol Pharmacol; 4: 625-631.
3. Amit SK, Zhiyang Zhao (2001): Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammaotry drugs with potential utility as anti cancer agents. Current Drug Targets; 2:79-106.
4. Jackson, L. M.; Hawkey, C. J. (1999): Gastrointestinal effects of COX-2 Inhibitors. Expert Opin. Invest. Drugs, 8, 963-971.
5. Scrip 2000, 2554, 20.
6. Steinbach G, Lynch PM, Phillips R K, Wallace MH, Hawk E, Gordon GB, Wakabyashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. (2000): The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Eng J Med; 342: 1946-1952.
7. For a review, see: Dannhardt, G.; Kiefer, W. (2001): Cyclooxygenase inhibitors - Current status and future prospects. Eur. J. Med. Chem., 36, 109-126.
8. Sunil et al. (2002): Design, Synthesis and Biological Evaluation of 2-Substituted Benzene sulphonamide Containing Novel Class of 1, 5-Diaryl Pyrazoles as Cyclooxy -genase-2 Inhibitors. J. Med. Chem. submitted.
9. R Mullangi et al.: Validated HPLC method for determination of DRF-4367, a novel COX-2 inhibitor, in rat plasma. J. Pharm. Biomed. App. (in preparation).
10. Gibaldi M. and Perrier D. (1982): Pharmacokinetics, 2nd edn. New York: Marcel Dekker, pp. 409-417.
11. Rao N.V.S. Mamidi, Ramesh Mullangi, Jagannath K, Ansar A.K. et al. (2002): Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats. Biopharmaceutics and Drug Disposition., 23, 7, 273-282.